Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

EGFR somatic mutations in lung tumors: radon exposure and passive smoking in former- and never-smoking U.S. women.

Taga M, Mechanic LE, Hagiwara N, Vähäkangas KH, Bennett WP, Alavanja MC, Welsh JA, Khan MA, Lee A, Diasio R, Edell E, Bungum A, Jang JS, Yang P, Jen J, Harris CC.

Cancer Epidemiol Biomarkers Prev. 2012 Jun;21(6):988-92. doi: 10.1158/1055-9965.EPI-12-0166. Epub 2012 Apr 20.

2.

CpG island hypermethylation in human astrocytomas.

Wu X, Rauch TA, Zhong X, Bennett WP, Latif F, Krex D, Pfeifer GP.

Cancer Res. 2010 Apr 1;70(7):2718-27. doi: 10.1158/0008-5472.CAN-09-3631. Epub 2010 Mar 16.

3.

Cigarette smoking, body mass index, gastro-esophageal reflux disease, and non-steroidal anti-inflammatory drug use and risk of subtypes of esophageal and gastric cancers by P53 overexpression.

Figueroa JD, Terry MB, Gammon MD, Vaughan TL, Risch HA, Zhang FF, Kleiner DE, Bennett WP, Howe CL, Dubrow R, Mayne ST, Fraumeni JF Jr, Chow WH.

Cancer Causes Control. 2009 Apr;20(3):361-8. doi: 10.1007/s10552-008-9250-6. Epub 2008 Nov 7.

4.

Radon, secondhand smoke, glutathione-S-transferase M1 and lung cancer among women.

Bonner MR, Bennett WP, Xiong W, Lan Q, Brownson RC, Harris CC, Field RW, Lubin JH, Alavanja MC.

Int J Cancer. 2006 Sep 15;119(6):1462-7.

5.

Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma.

Burke L, Flieder DB, Guinee DG, Brambilla E, Freedman AN, Bennett WP, Jones RT, Borkowski A, Caporaso NA, Fleming M, Trastek V, Pairolero P, Tazelaar H, Midthun D, Jett JR, Liotta LA, Travis WD, Harris CC.

Clin Cancer Res. 2005 Jan 1;11(1):232-41.

6.

Elevated frequency of ATM gene missense mutations in breast cancer relative to ethnically matched controls.

Sommer SS, Buzin CH, Jung M, Zheng J, Liu Q, Jeong SJ, Moulds J, Nguyen VQ, Feng J, Bennett WP, Dritschilo A.

Cancer Genet Cytogenet. 2002 Apr 1;134(1):25-32.

PMID:
11996792
7.

p53 and K-ras mutations in lung cancers from former and never-smoking women.

Vähäkangas KH, Bennett WP, Castrén K, Welsh JA, Khan MA, Blömeke B, Alavanja MC, Harris CC.

Cancer Res. 2001 Jun 1;61(11):4350-6.

8.

An in-frame deletion in the alpha(2C) adrenergic receptor is common in African--Americans.

Feng J, Zheng J, Gelernter J, Kranzler H, Cook E, Goldman D, Jones IR, Craddock N, Heston LL, Delisi L, Peltonen L, Bennett WP, Sommer SS.

Mol Psychiatry. 2001 Mar;6(2):168-72.

9.

Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease.

Hussain SP, Amstad P, Raja K, Ambs S, Nagashima M, Bennett WP, Shields PG, Ham AJ, Swenberg JA, Marrogi AJ, Harris CC.

Cancer Res. 2000 Jul 1;60(13):3333-7.

10.

Five missense variants in the amino-terminal domain of the glucocorticoid receptor: no association with puerperal psychosis or schizophrenia.

Feng J, Zheng J, Bennett WP, Heston LL, Jones IR, Craddock N, Sommer SS.

Am J Med Genet. 2000 Jun 12;96(3):412-7.

PMID:
10898924
11.

Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons.

Smith LE, Denissenko MF, Bennett WP, Li H, Amin S, Tang M, Pfeifer GP.

J Natl Cancer Inst. 2000 May 17;92(10):803-11.

PMID:
10814675
12.

RESPONSE: re: environmental tobacco smoke, genetic susceptibility, and risk of lung cancer in never-smoking women

Bennett WP, Alavanja MC, Harris CC.

J Natl Cancer Inst. 2000 May 3;92(9):760A-761. No abstract available.

PMID:
10793124
13.

RESPONSE: re: environmental tobacco smoke, genetic susceptibility, and risk of lung cancer in never-smoking women

Bennett WP, Alavanja MC, Harris CC.

J Natl Cancer Inst. 2000 May 3;92(9):760-1. No abstract available.

PMID:
10793122
14.

Human hemangiosarcomas have a common polymorphism but no mutations in the connexin37 gene.

Saito T, Krutovskikh V, Marion MJ, Ishak KG, Bennett WP, Yamasaki H.

Int J Cancer. 2000 Apr 1;86(1):67-70.

15.

Environmental tobacco smoke, genetic susceptibility, and risk of lung cancer in never-smoking women.

Bennett WP, Alavanja MC, Blomeke B, Vähäkangas KH, Castrén K, Welsh JA, Bowman ED, Khan MA, Flieder DB, Harris CC.

J Natl Cancer Inst. 1999 Dec 1;91(23):2009-14.

PMID:
10580025
16.

Molecular epidemiological study of non-small-cell lung cancer from an environmentally polluted region of Poland.

Rusin M, Butkiewicz D, Malusecka E, Zborek A, Harasim J, Czyzewski K, Bennett WP, Shields PG, Weston A, Welsh JA, Krzyzowska-Gruca S, Chorazy M, Harris CC.

Br J Cancer. 1999 Jul;80(9):1445-52.

17.

Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer.

Bennett WP, Hussain SP, Vahakangas KH, Khan MA, Shields PG, Harris CC.

J Pathol. 1999 Jan;187(1):8-18. Review.

PMID:
10341702
18.

p53 mutation spectrum in relation to GSTM1, CYP1A1 and CYP2E1 in surgically treated patients with non-small cell lung cancer.

Przygodzki RM, Bennett WP, Guinee DG Jr, Khan MA, Freedman A, Shields PG, Travis WD, Jett JR, Tazelaar H, Pairolero P, Trastek V, Liotta LA, Harris CC, Caporaso NE.

Pharmacogenetics. 1998 Dec;8(6):503-11.

PMID:
9918134
19.

Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer.

Ambs S, Bennett WP, Merriam WG, Ogunfusika MO, Oser SM, Harrington AM, Shields PG, Felley-Bosco E, Hussain SP, Harris CC.

J Natl Cancer Inst. 1999 Jan 6;91(1):86-8. No abstract available.

PMID:
9890175
20.

p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells.

Ambs S, Merriam WG, Ogunfusika MO, Bennett WP, Ishibe N, Hussain SP, Tzeng EE, Geller DA, Billiar TR, Harris CC.

Nat Med. 1998 Dec;4(12):1371-6.

PMID:
9846573
21.

Loss of heterozygosity in sporadic oesophageal tumors in the tylosis oesophageal cancer (TOC) gene region of chromosome 17q.

von Brevern M, Hollstein MC, Risk JM, Garde J, Bennett WP, Harris CC, Muehlbauer KR, Field JK.

Oncogene. 1998 Oct 22;17(16):2101-5.

22.

Vascular endothelial growth factor and nitric oxide synthase expression in human lung cancer and the relation to p53.

Ambs S, Bennett WP, Merriam WG, Ogunfusika MO, Oser SM, Khan MA, Jones RT, Harris CC.

Br J Cancer. 1998 Jul;78(2):233-9.

23.

Up-regulation of inducible nitric oxide synthase expression in cancer-prone p53 knockout mice.

Ambs S, Ogunfusika MO, Merriam WG, Bennett WP, Billiar TR, Harris CC.

Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8823-8.

24.

Mutation analysis of the Smad2 gene in human colon cancers using genomic DNA and intron primers.

Takenoshita S, Tani M, Mogi A, Nagashima M, Nagamachi Y, Bennett WP, Hagiwara K, Harris CC, Yokota J.

Carcinogenesis. 1998 May;19(5):803-7.

PMID:
9635866
25.

Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancer.

Burke L, Khan MA, Freedman AN, Gemma A, Rusin M, Guinee DG, Bennett WP, Caporaso NE, Fleming MV, Travis WD, Colby TV, Trastek V, Pairolero PC, Tazelaar HD, Midthun DE, Liotta LA, Harris CC.

Cancer Res. 1998 Jun 15;58(12):2533-6. Erratum in: Cancer Res 1998 Aug 1;58(15):3488.

26.

Anti-p53 antibodies in patients with Barrett's esophagus or esophageal carcinoma can predate cancer diagnosis.

Cawley HM, Meltzer SJ, De Benedetti VM, Hollstein MC, Muehlbauer KR, Liang L, Bennett WP, Souza RF, Greenwald BD, Cottrell J, Salabes A, Bartsch H, Trivers GE.

Gastroenterology. 1998 Jul;115(1):19-27.

PMID:
9649454
27.

p21waf1/cip1 and transforming growth factor beta 1 protein expression correlate with survival in non-small cell lung cancer.

Bennett WP, el-Deiry WS, Rush WL, Guinee DG Jr, Freedman AN, Caporaso NE, Welsh JA, Jones RT, Borkowski A, Travis WD, Fleming MV, Trastek V, Pairolero PC, Tazelaar HD, Midthun D, Jett JR, Liotta LA, Harris CC.

Clin Cancer Res. 1998 Jun;4(6):1499-506.

28.

p53 mutations in cyclophosphamide-associated bladder cancer.

Khan MA, Travis LB, Lynch CF, Soini Y, Hruszkewycz AM, Delgado RM, Holowaty EJ, van Leeuwen FE, Glimelius B, Stovall M, Boice JD Jr, Tarone RE, Bennett WP.

Cancer Epidemiol Biomarkers Prev. 1998 May;7(5):397-403.

29.

hSmad5 gene, a human hSmad family member: its full length cDNA, genomic structure, promoter region and mutation analysis in human tumors.

Gemma A, Hagiwara K, Vincent F, Ke Y, Hancock AR, Nagashima M, Bennett WP, Harris CC.

Oncogene. 1998 Feb 19;16(7):951-6.

30.

Bcl-2 immunohistochemistry in a surgical series of non-small cell lung cancer patients.

Fleming MV, Guinee DG Jr, Chu WS, Freedman AN, Caporaso NE, Bennett WP, Colby TV, Tazelaar H, Abbondanzo SL, Jett J, Pairolero P, Trastek V, Liotta LA, Harris CC, Travis WD.

Hum Pathol. 1998 Jan;29(1):60-4.

PMID:
9445135
31.

Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression.

Ambs S, Merriam WG, Bennett WP, Felley-Bosco E, Ogunfusika MO, Oser SM, Klein S, Shields PG, Billiar TR, Harris CC.

Cancer Res. 1998 Jan 15;58(2):334-41.

32.

p53 mutations in esophageal tumors from a high incidence area of China in relation to patient diet and smoking history.

Bennett WP, von Brevern MC, Zhu SM, Bartsch H, Muehlbauer KR, Hollstein MC.

Cancer Epidemiol Biomarkers Prev. 1997 Nov;6(11):963-6.

33.

Genomic instability and telomerase activity in human bronchial epithelial cells during immortalization by human papillomavirus-16 E6 and E7 genes.

Coursen JD, Bennett WP, Gollahon L, Shay JW, Harris CC.

Exp Cell Res. 1997 Aug 25;235(1):245-53.

PMID:
9281374
34.

Mutation analysis of the transforming growth factor-beta type II receptor in human cell lines resistant to growth inhibition by transforming growth factor-beta.

Vincent F, Nagashima M, Takenoshita S, Khan MA, Gemma A, Hagiwara K, Bennett WP.

Oncogene. 1997 Jul 3;15(1):117-22.

35.

Differential effects of p53 mutants on the growth of human bronchial epithelial cells.

Coursen JD, Bennett WP, Khan MA, Forrester K, Pietenpol JA, Harris CC.

Mol Carcinog. 1997 Jul;19(3):191-203.

PMID:
9254886
36.

Absence of mutations in the transforming growth factor-beta type II receptor in sporadic lung cancers with microsatellite instability and rare H-ras1 alleles.

Takenoshita S, Hagiwara K, Gemma A, Nagashima M, Ryberg D, Lindstedt BA, Bennett WP, Haugen A, Harris CC.

Carcinogenesis. 1997 Jul;18(7):1427-9.

PMID:
9230292
37.

Serum, plasma and paraffin-embedded tissues as sources of DNA for studying cancer susceptibility genes.

Blömeke B, Bennett WP, Harris CC, Shields PG.

Carcinogenesis. 1997 Jun;18(6):1271-5.

PMID:
9214613
38.

FHIT mutations in human primary gastric cancer.

Gemma A, Hagiwara K, Ke Y, Burke LM, Khan MA, Nagashima M, Bennett WP, Harris CC.

Cancer Res. 1997 Apr 15;57(8):1435-7.

39.
40.

Integrity of p53 in hepatitis B x antigen-positive and -negative hepatocellular carcinomas.

Greenblatt MS, Feitelson MA, Zhu M, Bennett WP, Welsh JA, Jones R, Borkowski A, Harris CC.

Cancer Res. 1997 Feb 1;57(3):426-32.

41.

Sporadic and Thorotrast-induced angiosarcomas of the liver manifest frequent and multiple point mutations in K-ras-2.

Przygodzki RM, Finkelstein SD, Keohavong P, Zhu D, Bakker A, Swalsky PA, Soini Y, Ishak KG, Bennett WP.

Lab Invest. 1997 Jan;76(1):153-9.

PMID:
9010458
42.

p53 mutations and occupational exposures in a surgical series of lung cancers.

Harty LC, Guinee DG Jr, Travis WD, Bennett WP, Jett J, Colby TV, Tazelaar H, Trastek V, Pairolero P, Liotta LA, Harris CC, Caporaso NE.

Cancer Epidemiol Biomarkers Prev. 1996 Dec;5(12):997-1003.

43.

Circulating anti-p53 antibodies in esophageal cancer patients are found predominantly in individuals with p53 core domain mutations in their tumors.

von Brevern MC, Hollstein MC, Cawley HM, De Benedetti VM, Bennett WP, Liang L, He AG, Zhu SM, Tursz T, Janin N, Trivers GE.

Cancer Res. 1996 Nov 1;56(21):4917-21.

44.

Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer.

Trivers GE, De Benedetti VM, Cawley HL, Caron G, Harrington AM, Bennett WP, Jett JR, Colby TV, Tazelaar H, Pairolero P, Miller RD, Harris CC.

Clin Cancer Res. 1996 Oct;2(10):1767-75.

45.

Semiautomated sequence-specific mutation detection of the human K-ras oncogene using "cold" SSCP analysis.

Hruszkewycz AM, Delgado RM, Khan MA, Bennett WP.

Clin Chem. 1996 Oct;42(10):1717-9. No abstract available.

46.

The genomic structure of the gene encoding the human transforming growth factor beta type II receptor (TGF-beta RII).

Takenoshita S, Hagiwara K, Nagashima M, Gemma A, Bennett WP, Harris CC.

Genomics. 1996 Sep 1;36(2):341-4.

PMID:
8812462
47.

Mutation analysis of the transforming growth factor beta type II receptor in sporadic human cancers of the pancreas, liver, and breast.

Vincent F, Hagiwara K, Ke Y, Stoner GD, Demetrick DJ, Bennett WP.

Biochem Biophys Res Commun. 1996 Jun 25;223(3):561-4.

PMID:
8687435
48.

An aflatoxin-associated mutational hotspot at codon 249 in the p53 tumor suppressor gene occurs in hepatocellular carcinomas from Mexico.

Soini Y, Chia SC, Bennett WP, Groopman JD, Wang JS, DeBenedetti VM, Cawley H, Welsh JA, Hansen C, Bergasa NV, Jones EA, DiBisceglie AM, Trivers GE, Sandoval CA, Calderon IE, Munoz Espinosa LE, Harris CC.

Carcinogenesis. 1996 May;17(5):1007-12.

PMID:
8640905
49.

p53 mutations in lung cancer following radiation therapy for Hodgkin's disease.

De Benedetti VM, Travis LB, Welsh JA, van Leeuwen FE, Stovall M, Clarke EA, Boice JD Jr, Bennett WP.

Cancer Epidemiol Biomarkers Prev. 1996 Feb;5(2):93-8.

50.

p53 tumor suppressor gene: implications for iatrogenic cancer and cancer therapy.

De Benedetti V, Bennett WP, Greenblatt MS, Harris CC.

Med Pediatr Oncol Suppl. 1996;1:2-11. Review. No abstract available.

PMID:
8643042

Supplemental Content

Loading ...
Support Center